Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
- Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
- Top Leaders Stress Importance of Globalization in Addresses to Incoming New Graduates
April 4, 2012
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
- Shionogi Acquires Global Rights for OncoTheraphy’s Cancer Vaccines
April 2, 2012
- Kyowa Kirin’s Expected Mainstay POTELIGEO Approved
April 2, 2012
- GSK, DSP Begin Copromotion of Paxil CR Tablets from April
April 2, 2012
- Toray, Taiho Terminate Co-Development of β3-Adrenoceptor Agonist
April 2, 2012
- NanoCarrier Enters into Joint Research Agreement with Eisai for Its Drug Discovery Platform Technology
April 2, 2012
- Astellas Enters into Partnership with US Company to Develop, Market Fidaxomicin in Japan
April 2, 2012
- Novartis Files for Add’l Indication of DME for Lucentis
April 2, 2012
- Tempstaff, IUK to Form PV Management Joint Venture in May
March 30, 2012
- Astellas, Pfizer Extend Lipitor Licensing Term
March 30, 2012
- Daiichi Sankyo Enters Research Collaboration Agreement on Diabetes Therapy with US Venture Company
March 30, 2012
- Otsuka Chemical to Split Up Glycotechnology Laboratory to Make It New Company
March 30, 2012
- More Than 70% of Doctors Say “Frequency of Meetings Will Not Change” Despite Review of Entertainment: CareNet Survey
March 29, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…